Novartis Chief Joins AI Company Board as Pharma Explores New Tech Partnerships

Novartis CEO Vas Narasimhan has joined the board of Anthropic, the artificial intelligence company, marking a significant move by a major pharmaceutical executive into the AI sector. The appointment comes as the biotech industry increasingly explores applications of large language models and machine learning in drug discovery and development.

Narasimhan's board position at Anthropic signals Novartis's commitment to integrating AI capabilities into its research operations. Anthropic, founded in 2021, has raised over $7 billion in funding to date and develops large language models used across industries including healthcare and scientific research.

The move reflects a broader trend in pharmaceuticals. Revolution Medicines closed a $2 billion fundraise on April 15, 2026, driven by positive Phase 3 trial results for daraxonrasib, its pancreatic cancer treatment, which doubled median overall survival in patients. The financing—double the company's initial target—demonstrates investor appetite for biotech firms advancing late-stage candidates.

Separately, Bain Capital unveiled Beeline Medicines, a new startup built to develop five immunology drugs licensed from Bristol Myers Squibb. The move follows Bain's initial licensing agreement with BMS announced in summer 2025. Industry observers view the Beeline launch as evidence that established pharmaceutical assets continue attracting venture capital investment, even as companies seek partnerships with technology firms.

Narasimhan's appointment to Anthropic's board suggests Novartis sees AI as central to future drug development strategy. The appointment was first reported by STAT News on April 15, 2026.

Context

Pharmaceutical companies have accelerated AI adoption over the past three years. In 2023, Eli Lilly partnered with Exscientia to use AI for drug discovery, while Pfizer expanded its computational chemistry capabilities. The sector has invested billions in AI startups and internal AI divisions, recognizing that machine learning can accelerate target identification, molecular design, and clinical trial recruitment.

Novartis previously committed $200 million to AI research partnerships in 2024. Narasimhan has publicly stated that AI will reshape drug development timelines, potentially reducing the average 10-year development cycle. His board seat at Anthropic positions Novartis to influence how AI models are adapted for pharmaceutical applications.

What's Next

Novartis will likely announce specific AI-driven initiatives in drug discovery within the next 12 months, potentially leveraging Anthropic's models for literature analysis and molecular research. Narasimhan's dual role as both Novartis CEO and Anthropic board member creates a direct channel for technology transfer between the companies.

The broader question is whether other major pharmaceutical firms will follow suit. If Novartis demonstrates measurable efficiency gains from AI-assisted research, competitors including Roche, Merck, and Johnson & Johnson may accelerate their own AI board appointments and partnerships.